Tomahawk, WI 09/05/2014 (Basicsmedia) – Tesla Motors Inc. (NASDAQ:TSLA), Netflix, Inc. (NASDAQ:NFLX) Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) remain CNBC’s ‘Mad Money’ analyst, Jim Cramer, top picks, when in pursue of high momentum in the market.

 Tesla Motors Inc. (NASDAQ:TSLA) has enjoyed an impressive run in the market, surging from lows of $30 a share to highs of $250 as of last year. The momentum seems to have picked up this year as the stock is already up by 90.15% trading at highs of $280, with Cramer maintaining it could go even higher in the coming months.

Cramer attributes Tesla Motors Inc. (NASDAQ:TSLA)’s impressive run in the market to its CEO, Elon Musk, who seem to be doing all that is needed to spur growth through innovative products.

“[…] Musk is a visionary he has always known that Tesla will revolutionize the auto industry and despite being knocked down by the Media and Wall Street analysts countless times, he has always gotten up and responded by Delivering,” said Mr. Cramer.

Deutsche Bank AG (USA) (NYSE:DB) according to Cramer has already predicted that Tesla has the potential to sell up to half million cars annually, raising the company’s prospects of growing even further in the future.

 Netflix, Inc. (NASDAQ:NFLX) according to Cramer, remains a consistent stock in the market having grown to become the biggest player in the video streaming business. Cramer argues that Netflix, Inc. (NASDAQ:NFLX) is operating in the video streaming industry on minimal competition, a move that has enabled it dictate prices to its advantage.

“[…] Netflix, Inc. (NASDAQ:NFLX) is raising prices, no one even seems to care. The company has developed a tremendous relationship with the viewers. […] it simply become a staple of at home entertainment. Over the last few years Netflix, Inc. (NASDAQ:NFLX) has changed the living room the way The Kroger Co. (NYSE:KR) has changed the Kitchen,” said Mr. Cramer.

 Additional of new Exciting content has also benefited Netflix seen by its customers always coming for more. Its stock is already 28.38% up this year, with Cramer maintaining the stock could register further rallying on the upside, heading into the close of the year.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the few stocks that has navigated the murky waters of the economic turmoil, growing from a low of $5 a share as of 2005 to highs of $350 this year. Innovative products for the mass market have worked to the company’s advantage according to Cramer.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) franchises continue to perform well with the company reportedly developing an anti-cholesterol agent that is expected to be of benefit to millions of people across the globe. Regeneron drive has come in the last two years with its stock having more than doubled in the process according to Cramer.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.